Table 1.
Phase 111 clinical trials of anti-VEGF monoclonal antibody agents in advanced gastric cancer
| Variable | AVAGAST trial | AVATAR trial | REGARD trial | RAINBOW trial |
|---|---|---|---|---|
| Authors | Ohtsu et al. | Shen et al. | Fuchs et al. | Wilke et al. |
| Number of patients | 774 | 202 | 355 | 665 |
| 1st-arm | 387 | 100 | 238 | 330 |
| 2nd-arm | 387 | 102 | 117 | 335 |
| Setting | 1st-line | 1st-line | 2nd-line | 2nd-line |
| Treatment regimens | ||||
| 1st-arm | CT + Bev | CT + Bev | Ram + BSC | PTX + Ram |
| 2nd-arm | CT + placebo | CT + placebo | BSC | PTX + placebo |
| ORR (%) | ||||
| 1st-arm (n/%) | 46% | 41% | 3% | 28% |
| 2nd-arm | 34.4% | 34% | 3% | 16% |
| HR (95% CI) | 8.1 (0.6–16.6) | 7.02 (8.3–22.4) | ||
| p value | 0.0315 | 0.34 | ||
| TTP/PFS (in months) | ||||
| 1st-arm | 6.7 | 6.3 | 2.1 | 4.40 |
| 2nd-arm | 5.3 | 6.0 | 1.3 | 2.86 |
| HR (95% CI) | 0.80 (0.68–0.93) | 0.89 (0.66–1.21) | 0.483 (0.376–0.620) | 0.635 (0.536–0.752 |
| p value | 0.0037 | 0.47 | 0.0001 | 0.0001 |
| OS (in months) | ||||
| 1st-arm | 12.1 | 10.5 | 5.2 | 9.63 |
| 2nd-arm | 10.1 | 11.4 | 3.8 | 7.26 |
| HR (95% CI) | 0.87 (0.73–1.03) | 1.11 (0.79–156) | 0.77 (0.603–0.998 | 0.807 (0.678–0.962) |
| p value | 0.1002 | 0.56 | 0.047 | 0.0169 |
ORR median overall response rate, TTP median time to progression, PFS median progression-free survival, OS median overall survival, T capecitabine, C cisplatin, Bev bevacizumab, HR hazard ratio, CI confidence interval, Ram ramucirumab, BSC best supportive care, PTX paclitaxel